ClinicalTrials.gg
CompletedNCT02070224PRODIGEUpdated Feb 5, 2019

Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis

An interventional study of Serum and urine samples collections and Imaging (x-rays and MRI) in Knee Osteoarthritis, sponsored by Artialis. Completed at 2 sites in 2 countries. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-02-05.

Sponsored by Artialis · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Osteoarthritis, Knee with a site in Belgium — 6 open to participants now, 11 under way, none of them phase 3. Osteoarthritis, Knee · Belgium.

Planned enrollment
15th of 38
120 · median 86
Started
2014
with 3 others
No phase
25 of 46
6 open now
Registered
6th of 46
by date

Among the 46 studies in Osteoarthritis, Knee with a site in Belgium, this one is the 15th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2014, is one of 25 with no phase, and was the 6th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

6 of the 46 studies in Osteoarthritis, Knee with a site in Belgium are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Osteoarthritis, Knee with a site in Belgium, or all of them as a file.
02

Study summary

The purposes of this study are to assess the prognostic value of serum and urinary biomarkers Coll2-1 and Coll2-1NO2 at baseline, and their change over the first year, on the progression of knee osteoarthritis MRI scores at 12 months, on the progression of knee osteoarthritis clinical score at 12 months. Additionally, this study will search for correlations between serum and urinary biomarkers Coll2-1 and Coll2-1NO2 at baseline with the radiographic, MRI and clinical severity of knee osteoarthritis.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 45 to 80 years with a ≤ 40
  • With an uni- or bilateral femorotibial knee osteoarthritis associated or not with a femoro-patellar knee osteoarthritis
  • Responding to clinical and radiological criteria of the ACR
  • Symptomatic for more than 6 months (for the most painful knee)
  • K\&L radiological grade of Felson II or III
  • With a cartilage lesion identified during MRI and either at least 1 out of 4 MRI severity criteria:

    • bone oedema
    • meniscal lesion in the central region of the medial compartment
    • effusion without answer to
    • zone without cartilage
  • or at least 1 out of 3 clinical severity criteria:

    • genu varum>3°
    • previous meniscal surgery
    • known polyarthritis
    • effusion on the target knee
  • Sign an after being informed
  • Able to follow the instructions of the study
  • With an agreement from the physicians having established the diagnosis of osteoarthritis (if any) to give relevant information to the investigator
  • With health insurance (for France).

Exclusion criteria

Exclusion Criteria:

For osteoarthritis:

  • Isolated patellofemoral arthritis
  • Chondromatosis or villo-nodular synovioma of the knee
  • Recent trauma-induced knee pain
  • Joint disease due to joint dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, hemophilia, hemochromatosis, ...
  • inflammatory pathologies as rheumatoid polyarthritis, gout arthritis, infectious arthritis
  • Diseases that may interfere with the evaluation of osteoarthritis (radiculalgia of lower limbs, arteritis, ...)
  • Genu valgum (degree considered as pathological by the physician)

For previous treatments:

  • Treatment with strontium ranelate, bisphosphonates, SERM and PTH

For known associated diseases:

  • Serious associated diseases: severe liver or renal failure, uncontrolled cardiovascular disease, , or C
  • Knee tumor

For patients:

  • Patient who participated to a therapeutic clinical trial 3 months before the T0 inclusion visit
  • Patient who are the subject of a judicial protection measure or under guardianship
  • Pregnant woman

For MRI :

  • Patient with a pacemaker, an implantable defibrillator, neurosurgical clips, a neurostimulator, cochlear implant, a stent, an insulin pump
  • Patient with a ferromagnetic splinter in the body, or having wire sutures
  • Serious mobility problem (Parkinson, tremors)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Knee osteoarthritis

    Other: Serum and urine samples collections · Other: Imaging (x-rays and MRI)

Interventions

  • OtherSerum and urine samples collections

    Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)

  • OtherImaging (x-rays and MRI)

    MRI will be done at baseline and 12 month and x-rays will be done at baseline

06

What researchers measure

Primary outcomes

  1. MRI will be analysed with semiquantitative Whole-Organ Magnetic Resonance Imaging Scoring method (WORMS)

    Time frame: 12 month

Secondary outcomes

  1. Knee injury and Osteoarthritis Outcome Score (KOOS) and Visual Analogue Scales (VAS) for mean knee pain and global patient assessment of disease activity

    Time frame: 12 month

Other outcomes

  1. Knee prosthesis during the study

    Time frame: 12 month

  2. MRI cartilage volume (optional)

    Time frame: 12 month

  3. MRI T2 relaxation time (optional)

    Time frame: 12 month

  4. MRI MOAKS scoring (optional)

    Time frame: 12 month

07

Study locations

2 sites
  • University Hospital of Liege-CHU
    Liege, 4000, Belgium
  • University Hospital of Nancy
    Nancy, France
08

References and documents

Publications

  • Hick AC, Malaise M, Loeuille D, Conrozier T, Maugars Y, Pelousse F, Tits C, Henrotin Y. Cartilage Biomarkers Coll2-1 and Coll2-1NO2 Are Associated with Knee OA MRI Features and Are Helpful in Identifying Patients at Risk of Disease Worsening. Cartilage. 2021 Dec;13(1_suppl):1637S-1647S. doi: 10.1177/19476035211021892. Epub 2021 Jun 15. PubMed 34128409 ↗
  • Hick AC, Fonck M, Costes B, Cobraiville E, Pirson S, Garcia L, Labasse A, Vander Poelen S, Henrotin Y. Serum Levels of Coll2-1, a Specific Biomarker of Cartilage Degradation, Are Not Affected by Sampling Conditions, Circadian Rhythm, and Seasonality. Cartilage. 2021 Dec;13(1_suppl):540S-549S. doi: 10.1177/1947603519878489. Epub 2019 Oct 20. PubMed 31631693 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Feb 2019 and a completion of Feb 2019. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2014
First posted
Feb 25, 2014
Start
Jan 2014
Primary completionActual
Feb 2019
CompletionActual
Feb 2019
Last update
Feb 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02070224
Lead sponsor
Artialis
Responsible party
Sponsor
First posted
Feb 25, 2014
Start date
Jan 2014
Primary completion
Feb 2019
Completion
Feb 2019
Last update
Feb 5, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion